ClinicalTrials.gg
RecruitingNCT07174206FAPO-2Updated Sep 15, 2025

FAPO-2: Cardiac Patient Monitoring Tool for Clinical Observation and Arrhythmia Detection

An interventional study of Smartwatch - all data and Portable holter system in Heart Diseases, Atrial Fibrillation (AF) and Angina, Unstable, sponsored by University of Sao Paulo. Recruiting at 1 site in Brazil. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by University of Sao Paulo · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Feb 2025, registered Aug 2025).
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
520
Allocation
Non-randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Heart Diseases with a site in Brazil — 11 open to participants now, 12 under way, 3 of them phase 3. Heart Diseases · Brazil.

Planned enrollment
17th of 44
520 · median 274
Started
2025
with 4 others
No phase
21 of 48
7 open now
Primary completion
2026-01
later than 3 of 11 live
Registered
45th of 48
by date
Lead sponsor
5 of 48
University of Sao Paulo

Among the 48 studies in Heart Diseases with a site in Brazil, this one is the 17th largest by planned enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2025, is one of 21 with no phase, reaches primary completion later than 3 of the 11 other live ones, and was the 45th registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

11 of the 48 studies in Heart Diseases with a site in Brazil are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Heart Diseases with a site in Brazil, or all of them as a file.
02

Study summary

The FAPO-2 study (Patient Monitoring Tool for Clinical Observation and Arrhythmia Detection) is a prospective, interventional, non-randomized study designed to evaluate the feasibility, usability, clinical effectiveness, and cost-efficiency of a wearable-enabled remote monitoring strategy in adult cardiac patients. The intervention consists of active clinical management of patients via teleconsultations, triggered by automated alerts generated through wearable data integrated into a centralized digital platform. FAPO-2 will include patients with chronic cardiovascular conditions and those undergoing recent minimally invasive interventions. The central objective is to validate a structured model for early arrhythmia detection, remote risk stratification, and timely clinical action. A total of 520 patients aged ≥22 years will be enrolled, stratified by sex (1:1), and followed at the Heart Institute (InCor) of the University of São Paulo. Participants will be allocated into one of four protocol groups:

Group 1 - Pilot (n=15): Healthy volunteers monitored for \~14±3 days using both the smartwatch and a portable holter system to validate usability, skin tolerability, signal integrity, and data flow within the platform.

Group 2 - Extensive Outpatient Monitoring (n=150): Patients with chronic cardiovascular diseases monitored over a 45-day period. During 30 days, monitoring will be performed using a smartwatch to capture blood pressure, oxygen saturation, heart rate, and single-lead ECG. For 15 days, participants will use both the smartwatch (for HR and ECG) and a portable holter system.

Group 3 - Extensive Post-Intervention Monitoring (n=50): Patients recently undergoing procedures such as angioplasty, TAVI, or ablation, following the same monitoring protocol as Group 2.

Group 4 - Optimized Outpatient Monitoring (n=305): Patients with stable chronic cardiac disease monitored for 15±3 days, using both devices simultaneously for HR and ECG (smartwatch) and portable holter system.

03

Conditions studied

  • Heart Diseases
  • Atrial Fibrillation (AF)
  • Angina, Unstable

Keywords

  • Atrial Fibrillation
  • FAPO
  • PAOF
  • Telemonitoring
  • Digital Health
  • Arrhythmias
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with cardiovascular disease, of both sexes, aged over 22 years;
  • Provision of through signature of the Informed Consent Form (ICF);
  • Assentation to adhere to study procedures and requirements;
  • Patients indicated for outpatient follow-up due to a cardiovascular condition, or with clinical parameters indicating the need for conventional surgical or catheter-based interventions (e.g., catheter ablation for arrhythmias, transcatheter aortic valve implantation, percutaneous coronary intervention, etc.);
  • Low or no risk of skin injury, based on Braden Scale clinical criteria or clinical team assessment

Exclusion criteria

Exclusion Criteria:

  • Presence of skin conditions, such as vitiligo, lupus, or atopic dermatitis, as well as tattoos on the wrist that may interfere with the smartwatch's optical sensor readings;
  • Known sensitivity or history of allergic reactions to components of the wearable devices or related items, such as adhesives or electrodes;
  • Inability to properly use the wearable monitoring devices due to physical, cognitive, or technological limitations;
  • Presence of a peripherally inserted central catheter (PICC) or arteriovenous fistula;
  • Presence of implanted cardiac devices, such as pacemakers, defibrillators, or cardiac resynchronization devices, which prevent acquisition via smartwatch;
  • Diagnosis of conditions associated with narrowing or obstruction of the aorta and subclavian arteries (e.g., Stanford Type A chronic aortic dissection, Takayasu arteritis, Subclavian Steal Syndrome, or Kawasaki disease), which may cause discrepancies in blood pressure between upper limbs and interfere with study assessments.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
520 participants (estimated)

Study arms

  • Experimental
    Pilot Group

    Healthy volunteers monitored for \~14±3 days using both a smartwatch and a portable holter system to validate usability, skin tolerability, signal integrity, and data flow within the platform.

    Device: Smartwatch - all data · Device: Portable holter system · Procedure: Telemonitoring · Other: AI Model Development

  • Active comparator
    Extensive Ambulatory Monitoring Group

    Patients with chronic cardiovascular diseases monitored over 45±3 days. For 30 days, participants use the smartwatch to collect blood pressure, oxygen saturation (SpO2), heart rate (HR), and sigle-lead ECG. Also, for 15 days, participants use both smartwatch (HR and ECG only) and portable holter system simultaneously, with the patch providing continuous ECG monitoring.

    Device: Smartwatch - all data · Device: Portable holter system · Procedure: Telemonitoring · Other: AI Model Development

  • Active comparator
    Extensive Post-Intervention Monitoring

    Patients who have recently undergone minimally invasive cardiovascular procedures such as angioplasty, transcatheter aortic valve implantation (TAVI), or catheter ablation. Monitoring occurs over 45±3 days. For 30 days, participants use the smartwatch to collect blood pressure, oxygen saturation (SpO2), heart rate (HR), and single-lead ECG. Also, for 15 days, both the smartwatch (HR and ECG only) and the portable holter system are used simultaneously, with the portable holter system providing continuous ECG monitoring.

    Device: Smartwatch - all data · Device: Portable holter system · Procedure: Telemonitoring · Other: AI Model Development

  • Active comparator
    Optimized Outpatient Monitoring

    Patients with stable chronic cardiac disease monitored for 15±3 days using both the smartwatch captures heart rate and single-lead ECG, while the portable holter system provides continuous ECG monitoring.

    Device: Portable holter system · Procedure: Telemonitoring · Other: AI Model Development · Device: Smartwatch - ECG and HR

Interventions

  • DeviceSmartwatch - all data

    Single-lead ECG, blood pressure (BP), oxygen saturation (SpO2), and continuous heart rate (HR).

  • DevicePortable holter system

    continuous ECG monitoring for 14 days for comparison with the data from the smartwatch

  • ProcedureTelemonitoring

    Remote consultations triggered by critical alerts based on predefined thresholds.

  • OtherAI Model Development

    Data analysis using artificial intelligence for prioritization of patients based on health data collected from wearables.

  • DeviceSmartwatch - ECG and HR

    Single-lead ECG and continuous heart rate (HR)

06

What researchers measure

Primary outcomes

  1. Incidence and number of Atrial Fibrillation (AF) events detected

    Incidence and total number of AF events detected, stratified by study group and device type (smartwatch, portable Holter). This allows assessment of AF detection rate across different monitoring protocols and devices during the follow-up period.

    Time frame: During the monitoring period for each group, as specified (14-45 days depending on group)

  2. Number of critical health alerts generated by the FAPO-SI³ platform

    Alerts categorized by physiological parameter: blood pressure (BP), heart rate (HR), and oxygen saturation (SpO₂). Mean clinical response time to alerts will be calculated per patient during their respective monitoring period, allowing assessment of platform responsiveness and clinical workflow efficiency.

    Time frame: During the monitoring period for each group, as specified (14-45 days depending on group)

  3. Patient risk classification generated by the AI model

    Distribution of patients across AI-generated risk categories (e.g., low, moderate, high) based on physiological and biometric data collected from the smartwatch and portable Holter system during the monitoring period.

    Time frame: During the monitoring period for each group, as specified (14-45 days depending on group)

Secondary outcomes

  1. Patient risk classification generated by the AI model

    Distribution of patients across AI-generated risk categories adapted from the Manchester Triage System. The algorithm will classify patients into risk levels (e.g., immediate, very urgent, urgent, standard, non-urgent) based on physiological and biometric data collected from the smartwatch and portable Holter system during the monitoring period.

    Time frame: During the monitoring period for each group, as specified (14-45 days depending on group)

  2. Adverse events related to device use

    Incidence of device-related adverse events including skin lesions (MARSI), allergic reactions, and discomfort (graded using validated scales) reported during the monitoring period.

    Time frame: From enrollment through the monitoring period, up to 45 days depending on study group

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Participant monitoring will be conducted by the multidisciplinary team via the SI³ platform, allowing near real-time detection of clinical events and prompt intervention. After study completion, all data will be anonymized and analyzed by the InCor team. De-identified datasets may be shared with the sponsor and affiliated entities. No personally identifiable information will be disclosed. All data sharing will comply with ethical and legal data protection standards.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Individual participant data (IPD) and supporting documentation will be made available exclusively to the study sponsor following the completion of the clinical study. There is no defined end date, as the sponsor will assume full custodianship of the data upon transfer. No public sharing of the data is planned.

Access criteria: Access to IPD and supporting information will be restricted to the study sponsor, in accordance with contractual agreements and applicable data protection regulations. The sponsor will have full authority over data access, management, and potential secondary use.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jan 2026, 11 months after the start.

Of 264 non-industry interventional studies with no phase under Heart Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 11 months is below that.

Counting every sponsor, half of 337 studies reached it within 25 months; a quarter within 11 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Sep 15, 2025
StartActual
Feb 7, 2025
Primary completionEst.
Jan 31, 2026
CompletionEst.
Feb 28, 2026
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07174206
Collaborators
Samsung Eletrônica da Amazônia Ltda
Responsible party
Fabio Biscegli Jatene (Full Professor of Cardiovascular Surgery at the University of São Paulo Medical School (FMUSP) and General Director of InCor-HCFMUSP, University of Sao Paulo) — Principal investigator
First posted
Sep 15, 2025
Start date
Feb 7, 2025
Primary completion
Jan 31, 2026 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Sep 15, 2025

Study contacts

Fabio B Jatene, PhD, MD
Contact
fabio.jatene@incor.usp.br
+551126615462
Rosangela Monteiro, PhD
Contact
rosangela.monteiro@incor.usp.br
+551126615197

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion